|
|
|
| Systematic evaluation and meta-analysis of Cinobufacin Injection in the treatment of malignant pleural and peritoneal effusion |
| JIANG Lujian1,2* ZHOU Qin2* ZHENG Junchao1,2 WANG Yitong1,2 TAN Yabin1,2 LI Binbin1,2 JIANG Miao3 ZUO Minghuan1,2 |
1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China;
3.College of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China |
|
|
|
Abstract Objective To evaluate the efficacy and safety of Cinobufacin Injection in the treatment of malignant pleural and peritoneal effusion and to make a meta-analysis. Methods Three Chinese databases (CNKI, WanFang, VIP) and three English databases (PubMed, Cochrane Library, EMbase) were systematically searched by computer from building database to June 2019. The randomized controlled clinical trial of Cinobufacin Injection in the treatment of malignant pleural and peritoneal effusion was screened according to the pre-established screening criteria, and meta-analysis was conducted with RevMan 5.3 software. Results A total of 145 literatures were retrieved and 9 studies were finally included, with a total sample size of 532 cases, 267 cases in experimental group and 265 cases in control group. The overall quality and sample size of the included studies were generally low. Meta analysis showed that total amount reduction of malignant pleural and peritoneal effusion (OR = 4.78, 95%CI: 3.12-7.32, P < 0.000 01), quality of life improvement (OR = 3.56, 95%CI: 2.06-6.18, P < 0.000 01) and myelosuppression (OR = 0.56, 95%CI: 0.33-0.94, P = 0.03) in Cinobufacin + Western medicine treatment group were all better than those in western medicine treatment group. Conclusion Cinobufacin Injection combined with Western medicine can effectively reduce total amount of malignant pleural and peritoneal effusion, improve the quality of life of patients, and reduce the incidence of myelosuppression in adverse reactions.
|
|
|
|
|
|
[1] 中国恶性胸腔积液诊断与治疗专家共识组.恶性胸腔积液诊断与治疗专家共识[J].中华内科杂志，2014，53（3）：252-256.
[2] Feller-Kopman DJ，Reddy CB，DeCamp MM，et al. Management of malignant pleural effusions. An officia ATS/STS/STR clinical practice guideline [J]. Am J Respir Crit Care Med，2018，198（7）：839-849.
[3] 施焕中.规范恶性胸腔积液的诊断与治疗[J].中华内科杂志，2014，53（3）：166-167.
[4] Avantunde AA，Parsons SL. Pattern and prognostic factors in patients with malignantperitoneal effussion：a retrospective study [J]. Ann Oncol，2007，18（5）：945-949.
[5] 顾筱莉，陈萌蕾，刘明辉，等.晚期恶性肿瘤合并恶性腹腔积液患者引流及灌注治疗的疗效分析[J].中国癌症杂志，2015，25（12）：994-998.
[6] 龙婧，郑琪，马婕群，等.恶性胸腔积液治疗的研究进展[J].医学综述，2019，25（3）：470-474.
[7] 袁莉，孙韬，周琴，等.华蟾素注射液腹腔灌注治疗恶性腹水102例的临床观察[J].中国医药导报，2014，11（22）：54-59.
[8] 周琴.华蟾素注射液胸腹腔灌注治疗恶性胸腹腔积液的临床研究[D].北京：北京中医药大学，2012.
[9] 左明焕，胡凯文，周琴，等.华蟾素对比白介素-2腹腔灌注治疗湿热型恶性腹水的临床观察[J].中国中医基础医学杂志，2014，20（8）：1101-1103.
[10] 孙燕，石元凯.临床肿瘤内科手册[M].5版.北京：人民卫生出版社，2007．
[11] Higgins JPT，Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0． the cochrane collaboration（Eds）[J]． N-S Arch Pharmacol，2011，5（2）：S38．
[12] 刘素艳，毛晓江，单冰菊，等.华蟾素联合顺铂腔内灌注治疗恶性胸腔积液的疗效观察[J].中国煤炭工业医学杂志，2017，20（7）：791-794.
[13] 冉之蓉.华蟾素联合顺铂腔内注射治疗恶性胸腹水[J].肿瘤，2007，27（8）：663-665.
[14] 王欢.华蟾素联合顺铂胸腔注药治疗癌性胸水[J].医学信息，2014，27（2）：92.
[15] 贾莉，韩玲爱.华蟾素联合胸腔内注射顺铂治疗恶性胸腔积液的疗效观察[J].临床内科杂志，2007，24（3）：205.
[16] 张彦，阎宁，张扶莉.华蟾素注射液联合化疗药物灌注治疗恶性胸腹水疗效观察[J].陕西中医，2014，35（10）：1284-1285.
[17] 张虹，徐悦涛，邹巧玲，等.华蟾素注射液联合顺铂腔内灌注治疗癌性胸腹水临床研究[J].中医学报，2016，31（8）：1096-1098.
[18] 陈为民.华蟾素注射液联合顺铂胸腔灌注治疗恶性胸腹积液临床观察[J].实用临床医药杂志，2013，17（23）：115-116.
[19] 胡敏.用胸腔置管引流术联合华蟾素、顺铂治疗恶性胸腔积液的效果对比[J].当代医药论丛，2014，12（20）：131-132.
[20] 王晓，曾震军，陈欣菊.华蟾素腹腔灌注治疗原发性肝癌恶性腹水的疗效观察[J].中国医药指南，2015，13（33）：20-21.
[21] 周琴，左明焕，李泉旺，等.基于中药寒热属性理论使用华蟾素治疗恶性胸腹水的临床研究[J].北京中医药大学学报：中医临床版，2013，20（4）：11-14.
[22] 王婷婷，徐国兴.华蟾素的药理作用研究及临床应用进展[J].国际眼科杂志，2009，9（7）：1330-1333. |
|
|
|
